When a Child with Immune Thrombocytopenia Experiences Life-threatening Bleeding

Abstract

Wenn ein Kind mit Thrombozytopenie lebensbedrohlich blutet▶ Persistence of sequelae (mainly stroke) is observed in circa 25 % of survivors of ICH. P. ImbachPediatric Oncology / Hematology, University Children ' s Hospital Basel, SwitzerlandDownloaded by: Karolinska Institutet. Copyrighted material.

Allogeneic Hematopoietic Stem Cell Transplantation in Glanzmann Thrombasthenia Complicated by Platelet Alloimmunization

“…In one case, this resulted in engraftment failure with subsequent retransplantation [1] , while in other cases the antibody disappeared after conditioning [1,3,4,6] . Immune-mediated thrombocytopenia has been treat ed with various medications, including intravenous immunoglobulins (IVIG), corticosteroids, immunosuppression, and other agents directed against cells that either produce antibodies or modify the immune response [2,5,8,10,11] . IVIG have been reported to be eff ective in reversing immune thrombocytopenia, as well as lowering levels of circulating autoantibodies in transplantation settings [4,5,8] .…”

“…Immune-mediated thrombocytopenia has been treat ed with various medications, including intravenous immunoglobulins (IVIG), corticosteroids, immunosuppression, and other agents directed against cells that either produce antibodies or modify the immune response [2,5,8,10,11] . IVIG have been reported to be eff ective in reversing immune thrombocytopenia, as well as lowering levels of circulating autoantibodies in transplantation settings [4,5,8] . IVIG in addition to repeated partial plasma exchange were essential treatment elements for this young patient.…”

Acute Psychosis in an Adolescent Girl During Treatment for Advanced Nodular Lymphocyte-Predominant Hodgkin's Lymphom

“…Nevertheless, rituximab has been used off -label for the treatment of other life-threatening diseases in children and adolescents as an individual therapy regime, e.g. immune thrombozytopenia [8,11] , hemophagocytic lymphohistiocytosis [9] . However, since the patient needed an eff ective oncological treatment while urgently requiring a locked psychiatric therapy and at that time only very few neurologic side-eff ects of rituximab have been described [4] , a treatment with rituximab was initiated, although rituximab is neither for children nor for adults licensed for the treatment of nLPHL.…”